Clinical Trial COGACCL1131


A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFi Following Allogeneic Hematopoietic Cell Transplantation (HCT)

Principal Investigator(s)

Adam Esbenshade


  • Protocol No. COGACCL1131
  • Open Date: 06/12/2013
  • Staging: Phase III
  • Age Group: Both Child and Adult
  • Scope: International
  • Objective: To determine if Caspofungin is associated with a lower incidence of proven/probable IFI during the first 42 days following allogeneic HCT at high-risk for IFI compared with azole (fluconazole or voriconazole) prophylaxis
  • Disease Sites: Pediatrics
  • Therapies: Therapy (NOS)
  • Drugs: Caspofungin; Fluconazole
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01503515
  • Secondary Protocol No: ACCL1131



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.